11:01 AM EDT, 09/15/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday the Canadian province of Alberta has now listed the company's Vraylar, or cariprazine, antipsychotic medication on its Health Drug Formulary.

Vraylar is indicated to treat schizophrenia in adults, the company said, adding that the medication is already listed in all provinces and by federal programs including Non-Insured Health Benefits, Correctional Service Canada, and Veterans Affairs Canada.

AbbVie ( ABBV ) said it is jointly developing Vraylar with Gedeon Richter.

Shares of the company were down 1.3% in recent Monday trading.

Price: 215.43, Change: -2.91, Percent Change: -1.33